One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders

PURPOSE: A sub-population of patients with diabetic macular edema (DME) responds less effectively to off-label use of Bevacizumab. Approval of Aflibercept for DME has offered Bevacizumab nonresponders an alternative therapeutic option. Herein, we investigate the anatomical and functional changes ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Salimi, Ali, Vila, Natalia, Modabber, Milad, Kapusta, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Special Focus on Anti-VEGF, Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933844/
https://www.ncbi.nlm.nih.gov/pubmed/33463593
http://dx.doi.org/10.4103/ijo.IJO_459_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933844/
https://www.ncbi.nlm.nih.gov/pubmed/33463593
http://dx.doi.org/10.4103/ijo.IJO_459_20

Ejemplares similares